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Abstract
DNA microarrays are a relatively new technology that can simultaneously mea-
sure the expression level of thousands of genes. They have become an im-
portant tool for a wide variety of biological experiments. One of the most com-
mon goals of DNA microarray experiments is to identify genes associated with
biological processes of interest. Conventional statistical tests often produce
poor results when applied to microarray data due to small sample sizes, noisy
data, and correlation among the expression levels of the genes. Thus, novel
statistical methods are needed to identify significant genes in DNA microarray
experiments. This article discusses the challenges inherent in DNA microarray
analysis and describes a series of statistical techniques that can be used to
overcome these challenges. The problem of multiple hypothesis testing and its
relation to microarray studies is also considered, along with several possible
solutions.
High-dimensional biological data sets have become increasingly common in
recent years. Examples include data collected from DNA microarrays, com-
parative genome hybridization experiments, mass spectrometry, genome-wide
association studies, and DNA/RNA sequencing. These new technologies have
revolutionized our understanding of the genetics of human disease and numer-
ous other biological processes. However, statistical analysis of such data sets
is challenging for several reasons. These data sets are high-dimensional, and
the sample sizes are often small. Moreover, many of these data sets tend to
be “noisy,” and the correlation between the features that are measured can be
complex. For these reasons conventional statistical methods often produce un-
satisfactory results when applied to modern high-dimensional biological data.
The present study focuses on one of the most common problems in the analy-
sis of high-dimensional biological data, which is the identification of significant
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genes in DNA microarray studies. This is one of the best-studied problems in
the analysis of high-dimensional biological data sets, and many of the methods
that are applied to this problem may also be applied to other types of high-
dimensional biological data. In a typical microarray study, one may wish to
identify genes that are associated with a disease or some other biological pro-
cess of interest. For example, one might attempt to identify genes associated
with a disease by collecting a set of biological samples from diseased patients
and another set of samples from healthy patients. Genes whose expression
levels differ between the diseased samples and the control samples may be
associated with the disease of interest. Alternatively, one might wish to identify
genes that may be used to predict the prognosis of patients with a specific type
of cancer. One might identify such genes by collecting tumor samples from
a cohort of cancer patients and searching for genes whose expression levels
are associated with the survival times of the patients. Ultimately, this informa-
tion may be used for personalized treatment of cancer and other diseases. If
the gene expression profile of a tumor indicates that the risk of metastasis is
high, then the cancer should be treated more aggressively than another tumor
whose gene expression suggests a low risk of metastasis.
This article consists of three main sections. In the first section, we will briefly
describe DNA microarray technology and how DNA microarray data is col-
lected. In the second section, we will provide a brief overview of some of the
methods that have been used to identify significant genes in DNA microarray
experiments. Numerous methods have been proposed in recent years, and
space does not permit a detailed discussion of all possible methods. We have
attempted to focus on several of the most commonly used approaches, along
with an overview of some of the common principles and techniques used in
these methods. We also briefly describe a few more recent methods for com-
bining information across genes. In the final section, we discuss the problem of
multiple hypothesis testing, which inevitably arises when identifying significant
features in high-dimensional data sets.
DNA Microarray Data
Overview of Molecular Biology
Each organism’s genetic information is contained in a molecule called deoxyribonu-
cleic acid, more commonly known as DNA. DNA is a double-stranded molecule that
is a chain of four possible nucleotides, namely adenine (A), cytosine (C), guanine (G),
and thymine (T). The two strands of DNA are joined to one another by hydrogen bonds
between nucleotides on the opposite strands. A always pairs with T, and G always pairs
with C. Thus, if the sequence of one strand of DNA is known, then the sequence of the
other stand is also known. Each such pair of bonded nucleotides is known as a base
pair.
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There are approximately 3.2 billion base pairs in the human genome (i.e. the entire
sequence of DNA in a given human cell)1. Different segments of DNA perform differ-
ent functions, and much of the DNA performs no known function. The DNA segments
of primary interest in most studies are the segments which contain instructions for
building proteins. These segments are known as genes, and they comprise about 1.5%
of the DNA sequence in humans2. Proteins perform most of the important functions
in cells, including metabolism, DNA replication and repair, and communication with
other cells.
The information contained in DNA is converted to proteins in a two-step process: In
the first step, known as transcription, a given sequence of DNA is transcribed into an
intermediary called messenger ribonucleic acid (mRNA), which is a single-stranded
molecule that contains a copy of the complements of the base sequence of the DNA.
The one difference is that thymine is replaced by uracil (U). In the second step, known
as translation, the sequence of base pairs in the mRNA is translated into a protein,
which is composed of a sequence of amino acids. Each set of three base pairs in the
mRNA corresponds to one of 20 amino acids, a relationship that is known as the ge-
netic code. This process by which the information in the sequence of DNA is converted
to mRNA and then to proteins is known as the fundamental dogma of molecular biol-
ogy. See Dudoit et al. 3 for a discussion of this process and its relationship to DNA
microarray data.
DNA Microarray Technology
An important implication of the fundamental dogma of molecular biology is that there
should be a strong association between the presence of a given protein in a cell and
the presence of the mRNA sequence that is transcribed to build that protein. If a pro-
tein is active in a given cell, there should be a large number of copies of the mRNA
sequence corresponding to that protein. Conversely, if a protein is not active in a cell,
there should be few copies of the corresponding mRNA sequence. Thus, DNA mi-
croarrays attempt to evaluate the presence or absence of proteins in a cell and their
relative abundance by measuring the relative abundance of the corresponding mRNA
sequences.
DNA microarrays measure the relative abundance of mRNA sequences in the cells in
a sample by taking advantage of complementary base pairing. Recall that in a DNA
(or RNA) sequence, C always pairs with G and A always pairs with T (or U). A DNA
microarray is typically constructed by placing an array of probes on a glass micro-
scope slide. Each probe consists of a sequence of nucleotides that is complementary
to the nucleotide sequence of a specific mRNA or its corresponding DNA sequence.
Thus, one can measure the expression level of a given gene by measuring the amount
of mRNA that hybridizes to the spot on the microarray corresponding to the gene.
Different forms of DNA microarrays exist, such as oligonucleotide microarrays4 and
cDNA microarrays5,6, but all of the most commonly used microarrays are based on this
principle.
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[Figure 1 about here.]
Figure 1 illustrates a typical (cDNA) microarray experiment. Two samples are col-
lected, namely an experimental sample and a control sample. For example, the ex-
perimental sample may contain tissue from a cancerous tumor, and the control sample
may contain non-cancerous tissue from the same location in the body. First, mRNA is
extracted from both samples. The extracted mRNA is treated with an enzyme called
reverse transcriptase to convert it to a complementary DNA (or cDNA) sequence. Then
each sample is treated with a fluorescent dye. Typically the red dye Cy5 and the green
dye Cy3 are used. Equal amounts of the two samples are then hybridized onto an array.
To determine which genes are expressed at a high (or a low) level in the experimental
group compared to the control group, one may measure the ratio of Cy5 to Cy3 at the
probe on the array corresponding to that gene. For example, suppose that the experi-
mental sample was treated with the red dye and the control sample was treated with the
green dye. Then a red spot on the array indicates that there was more mRNA for that
particular gene produced by the experimental group than the control group, indicating
that this gene is expressed at a higher level in the control group. An image of a DNA
microarray slide is shown in Figure 2.
[Figure 2 about here.]
Before microarray data is analyzed, the ratio of red dye to green dye at each spot on
the array is measured using an appropriate scanner. This ratio is stored in a large data
matrix. Typically each row of the data matrix contains all the measured expression
levels for a given gene, and each column of the data matrix corresponds to a particular
sample. Such a data set is often visualized in the form of a heat map, as shown in
Figure 3. The task of the microarray data analyst is to answer the biological question(s)
of interest using this data matrix.
[Figure 3 about here.]
It is important to attempt to remove extraneous variation in microarray data prior to data
analysis. Variations in design of the arrays, sample preparation and scanner reading can
produce “batch effects” where some subset of samples exhibit systematic differences
in gene expression that are unrelated to the biological process of interest. Failure to
account for such batch effects can result in spurious findings.7,8 Thus, normalization
is often necessary to remove batch effects. Numerous methods have been proposed
to normalize microarray data9–17. A detailed description of these normalization meth-
ods are beyond the scope of this review; see the aforementioned references for more
information.
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Methods for Identifying Significant Features in DNA Mi-
croarray Data
Perhaps the most common objective of microarray experiments is to identify genes that
are associated with a biological process of interest. For example, one may wish to iden-
tify genes associated with a disease of interest by comparing the expression levels of
genes in diseased samples to the corresponding expression levels in healthy samples.
Other outcomes of interest are also possible. For example, in cancer studies, one fre-
quently wishes to identify genes associated with the survival time of cancer patients.
The motivation is that genes that are associated with lower survival are likely to be
associated with more serious forms of cancer that require more aggressive treatment.
In statistical terms, one has a large number of features (genes) and an outcome variable
(e.g. disease versus control, survival time, etc.). The objective is to identify genes that
are associated with the outcome variable. In principle, this objective can be accom-
plished using conventional statistical methods. To compare the expression of genes
between two groups, one may calculate a t-test statistic for each gene. If there are
three or more groups, an ANOVA F-test statistic may be used. To find genes associated
with a continuous outcome variable, one may calculate a standardized regression co-
efficient, and to find genes associated with a survival outcome, one may calculate the
Cox score for each gene18,19.
However, these conventional methods often perform poorly on microarray data sets for
several reasons, which will be discussed in more detail below. DNA microarray data
sets are frequently noisy, and sample sizes are often small. Moreover, the gene ex-
pression levels are often highly correlated with one another, and failing to account for
this fact may result in a loss of power. Also, one will typically perform several thou-
sand hypothesis tests in a microarray experiment, so specialized methods are needed to
control for type I error.
Throughout the remainder of this section, we will assume that one is comparing two
different conditions using a t-test or a variation of the conventional t-test. However, the
methods discussed below are easily generalized to other test statistics, such as ANOVA
F-tests, standardized regression coefficients, and Cox scores.
Fold Change Methods
One simple method for identifying differentially expressed features is to compute the
average value of each feature under each condition and then compute the ratio of these
averages. If the ratio exceeds some arbitrary cutoff, then the difference is called “sig-
nificant.” For example, a gene may be called “significant” if the average expression
level of a gene is more than twice as large (or less than half as large) in one condition
compared to the other.
This approach has the benefit of simplicity, and it has been used in previous microarray
studies20,21. However, this method has some serious shortcomings. It is not based on
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a formal statistical test, so there is no simple way to calculate a p-value or confidence
interval or other measure of the statistical validity of the association. Moreover, it is
easy to see that this fold change has higher variance for genes expressed at lower levels,
which is true of the majority of genes in microarray studies22–24. For these reasons fold
change methods are generally accepted to be inferior to other methods for identifying
differentially expressed features25–29.
T -Tests
An alternative approach is to identify significant genes based on a two-sample t-test
of the null hypothesis that the mean expression level of the gene is the same under
both conditions. This approach has also been used in microarray studies30, and it has
several advantages over fold change methods. It is straightforward to calculate p-values
and confidence intervals using t-tests, and for large samples the distribution of the t-
statistic is independent of the overall expression level of the gene. In contrast, fold
change statistics have higher variance for genes expressed at low levels.
Unfortunately, using t-tests to identify differentially expressed genes can be problem-
atic when the sample size is small, which is commonly the case in microarray exper-
iments. It can be difficult to obtain accurate estimates of the variances of each group
when the sample sizes are small. In particular, if the the estimated variance of a gene is
small, which occurs frequently when a gene is expressed at low levels24, then the gene
may have a large t-statistic even if the fold change is small.
Alternative Versions of T -Tests
Given the shortcomings of t-tests described above, numerous authors have proposed
alternative versions of t-tests for identifying significant features in gene expression
data. Typically these methods combine data from all the genes to obtain a regularized
estimator of the variance of a particular gene. In general, such variance estimates are
biased. However, since the usual estimator of the variance has high variance when the
sample size is low, a biased estimator of the variance may have lower prediction error
than an unbiased estimator, since these biased estimators have lower variance than the
unbiased estimator. This is especially true when the sample size is small. See Hastie
et al. 31 for a more detailed discussion of this phenomenon, which is commonly referred
to as the “bias-variance trade-off.”
An example of the bias-variance trade-off is shown in Figure 4. Suppose the objective
is to predict y based on x given the data in the figure. If one predicts y using a linear
regression estimator based on x, the variance will be relatively low, but the bias will be
high, since it cannot model the nonlinear relationship between x and y. At the other
extreme, if one predicts y by interpolating the data with a smoothing spline, the bias
will be 0, since the interpolation function can model any arbitrary relationship between
x and y. However, the variance will be high, since the predicted values of y may change
drastically if such a model is fit to a new data set.
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[Figure 4 about here.]
Figure 5 shows how the bias and variance of a series of models varies as the complexity
of the model increases. Each model in this figure represents a smoothing spline32 fit
to the data from Figure 4. As the complexity of the model increases, the variance of
the model increases and the bias of the model decreases. One attempts to choose the
model complexity that minimizes the expected prediction error or mean squared error
(MSE), which can be shown to be equal to the sum of the variance, the square of the
bias, and an irreducible error term due to unexplainable variance in y 31.
[Figure 5 about here.]
These figures illustrate why a regularized (i.e. biased) estimator of the variance of the
genes may produce better results when identifying significant features based on mi-
croarray data. By regularizing the estimates of the variance, the complexity of each
individual model is reduced, increasing the bias of the model but decreasing the vari-
ance. If the decrease in variance is sufficient to offset the increase in bias, the accuracy
of the overall model may be increased.
One possible approach is to estimate the variance of each gene by using the pooled
estimator of the variance of all genes. Although this method has been used for several
microarray studies33–35, it also has some serious shortcomings. This obviously assumes
that the variance of the expression levels of all genes are approximately the same, which
is unlikely to be true in most situations. More importantly, since the denominator of
the t-test will be the same for all genes, this method is essentially equivalent to the fold
change method, since it selects the genes with the largest mean differences without
regard for the variance of an individual gene and thus suffers from the same drawbacks
as fold change methods. In terms of the bias-variance trade-off, this pooled variance
estimate has low variance but high bias.
An alternative approach is to combine the variance estimator of each gene with some
sort of pooled estimator of the variance across the genes. This avoids the high variance
that results from estimating the variance of each gene individually as well as the high
bias that results from relying entirely on a pooled variance estimate. For example, the
“Significance Analysis of Microarrays” (SAM) procedure of Tusher et al. 24 uses the
following test statistic:
ti =
X¯i − Y¯i
si + s0
(1)
Here ti represents the t-statistic for the ith gene, and X¯i and Y¯i represent the mean ex-
pression level of the gene under each experimental condition. The variance is estimated
by summing the estimated variance of the ith gene (denoted by si) and a normalizing
constant s0. This normalizing constant reduces the variance of the estimator of the vari-
ance and hence reduces the likelihood of obtaining false positive findings as a result of
genes whose estimated variance is small. Typically s0 is chosen to be some quantile
(such as the median) of the si’s across all of the genes. The SAM software is publicly
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available as an add-in for Microsoft Excel (http://www-stat.stanford.edu/ tibs/SAM/).
It is also implemented in the “samr” R package.
Other normalized estimators of the variance of microarray samples have been proposed.
For example Huber et al. 36 apply an arsinh transformation to the gene expression data
that is designed to produce stable variance estimates irrespective of the gene’s over-
all expression level. This method is implemented in the “vsn” R package (available
through the Bioconductor project at http://www.bioconductor.org). Cui et al. 37 com-
bine gene-specific and between-gene variance estimates using a James-Stein estima-
tor38. R code for implementing this method is available at
http://www.stjuderesearch.org/depts/biostats/documents/cui-Fstat.R. In general, any method
to reduce the variance in the estimates of the variances of the individual genes can pro-
duce more accurate results when the sample size is small.
Bayesian Methods
Bayesian methods can also be used to combine information across genes to avoid in-
accurate variance estimates as a result of small sample sizes. Typically these methods
impose some type of Bayesian prior distribution on the gene expression data and es-
timate the posterior distribution for each gene by combining information across all of
the genes. For example, Baldi and Long 39 impose a prior distribution on the variances
of the genes to obtain the following regularized t-test:
ti =
X¯i − Y¯i√
v0σ
2
0
+(n−1)s2
i
v0+n−2
(2)
In this expression X¯i, Y¯i, and si are defined as they were in (1). The parameter σ20 is
an estimator of the pooled variance across genes, which is calculated using data from
all the genes, and v0 is a tuning parameter that controls the relative contributions of
the gene-specific variance estimate and the global variance estimate. R code for imple-
menting this method is available at http://molgen51.biol.rug.nl/cybert/help/index.html.
Note that (2) is similar to (1) in that the denominator of the t-statistic consists of a lin-
ear combination of an estimator of the variance of gene i plus a pooled estimate of the
variance of all the genes. The similarity between the two expressions is not surprising.
In general Bayesian methods tend to produce biased parameter estimates, but these es-
timators may have lower variance/mean squared error than unbiased estimators, which
is the same motivation for considering the regularized variance estimators discussed
previously. Indeed, in some situations regularized frequentist parameter estimators can
be shown to be Bayesian estimators with the appropriate choice of prior40.
Other similar Bayesian approaches have also been proposed for different types of mi-
croarray problems41–45. In particular, the “limma” method of Smyth 44 uses an empir-
ical Bayes test statistic that consistently performed well in a recent study comparing
feature selection methods for microarray data46.
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Calculating P -Values
If a t-test (or other conventional parametric test, such as ANOVA or regression) is used
to test the null hypothesis of no association between the expression level of a given gene
and an outcome, then calculating the p-value for this null hypothesis is straightforward
if the assumptions of the test are satisfied. However, it may be dangerous to assume that
these test statistics are normally distributed when the sample size is small. Moreover,
as discussed previously, in many situations it is preferable to use biased estimators of
the variance of a gene’s expression level. When a biased estimator of the variance is
used, a t-statistic may no longer have a t distribution. Thus, alternative approaches
may be needed to compute p-values in these situations.
One possible alternative is to calculate p-values based on the permutation distribution
of the test statistic. Let tj denote the t-statistic (or other test statistic) associated with
gene j. Suppose the sample labels are then permuted K times, and let tj,k denote
the test statistic associated with gene j for the kth permuted data set. Then one can
estimate the p-value for gene j (denoted by pj) as follows:
pj =
1
K
K∑
k=1
I (|tj,k| > |tj |) (3)
Here I(x) denotes an indicator function that is equal to 1 if the condition is true and
0 otherwise. In other words, the p-value is estimated by counting the number of times
that the permuted version of the test statistic is “more extreme” than the original (unper-
muted) version of the test statistic. A very large (or very small) test statistic is unlikely
to occur by chance, so very few permuted data sets will produce a larger test statistic
and the p-value will be small. This approach is used by the “SAM” software package24
to calculate p-values.
This approach requires a choice of the number of permutations K . For small data sets,
one may simply evaluate all possible permutations. In the case where one wishes to
compare n1 samples from one condition to n2 samples from another condition using
a t-test (or variant thereof), there are a total of (n1+n2
n1
)
possible permutations. How-
ever, this would be computationally intractable for larger data sets, so it is common to
arbitrarily select a value of K = 1000 or an even larger number if more precision is
desired.
One possible problem with calculating p-values using (3) is that it can be difficult to
estimate p-values that are close to 0. If |tj | > |tj,k| for all k, then (3) implies that
pj = 0, which in reality all that can be inferred is that pj < 1/K . This is problematic
because certain methods for adjusting for multiple hypothesis testing in microarray
experiments require precise estimation of p-values that are very close to 0. See below
for more details.
There are a few possible solutions to this problem. The simplest approach is to increase
the value of K . This will solve the problem given sufficient computing power, but it
can be computationally intractable for large data sets. Another possibility is to pool the
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results of all the genes when calculating the permutation p-values. Suppose there are a
total of N genes in the experiment. Then we estimate pj as follows:
pj =
1
NK
N∑
i=1
K∑
k=1
I (|ti,k| > |tj |) (4)
In other words, rather than simply counting the number of times that the permuted test
statistic for gene j is more extreme than the unpermuted test statistic for gene j, one
counts the number of times that the permuted test statistic for any gene is greater than
the permuted test statistic for gene j. This can increase the precision of the estimates
of pj without increasing the computational burden. See Hastie et al. 31 for a complete
discussion of calculating p-values based on the permutation distribution of the test
statistics.
Methods for Combining Information Across Genes
The methods discussed thus far assume that hypothesis tests will be performed on each
gene one at a time, and that the results of a hypothesis test on a given gene will not be
affected by the hypothesis tests performed on other genes. This strategy may be inef-
ficient on DNA microarray studies. Genes often act in pathways, meaning that several
genes may be involved with the same biological process and hence be activated and
deactivated simultaneously. If several related genes show evidence of differential ex-
pression at the same time, that is stronger evidence that the differential expression rep-
resents biological signal than if such a pattern were observed for a single gene. Several
methods have been proposed for combining information across genes when searching
for differentially expressed genes in microarray studies, which will be discussed below.
Biologically Motivated Methods
One approach for combining information across genes is to utilize known biological
relationships among the genes. Typically genes are classified into groups using biolog-
ical databases such as Gene Ontology47. Each group represents a set of biologically
similar genes. The most commonly used methods compare the number of significant
features in each group to the number expected if the genes in the group are not differ-
entially expressed. If there are an unusually high number of significant features in a
given group, that suggests that the pathway corresponding to the group is differentially
expressed.
One strategy for identifying pathways containing differentially expressed genes is known
as over-representation analysis (ORA). ORA first identifies a list of “significant” genes
using any of the previously described methods for detecting differentially expressed
genes. The M “most significant” genes are selected, which are typically the genes
with the smallest p-values. Then for each group of genes, Fisher’s exact test (or some
approximation thereof) is used to test the null hypothesis that the number of genes
called significant in each group does not exceed the number of genes expected to be
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called significant due to chance. Various implementations of ORA have been proposed
in the literature48–53, and it has been used in some microarray experiments54.
Despite the popularity of ORA, it has several shortcomings. Typically only the top M
genes are used to compute the ORA statistics, resulting in the loss of any information
available from genes not among the M most significant genes. The choice of M is
often arbitrary as well. Moreover, all of the top M genes are treated equally, meaning
that genes with extremely small univariate p-values are given the same weight as genes
whose univariate p-values are much larger. Finally, ORA considers the gene to be the
unit of analysis rather than the subject, which is inappropriate in virtually all real-world
situations. Among other issues, it implies that the gene sets should be independent of
one another, which is almost certainly not true in practice. See Pavlidis et al. 55 , Tian
et al. 56 , or Allison et al. 29 for more information on the shortcomings of ORA.
An alternative strategy that avoids the problems associated with ORA is gene set
enrichment analysis (GSEA). GSEA functions as follows: First, the genes are or-
dered according to their t-statistics or p-values or some other measure of univari-
ate statistical significance. Then for each group of genes, the distribution of the t-
statistics of the genes in the group is compared to the distribution of the genes not
in the group using a one-sided Kolmogorov-Smirnov statistic or some other similar
statistic. The idea is that if a group of genes is differentially expressed, then the
distribution of the t-statistics among that set of genes should be different than the
distribution of the t-statistics among the remaining genes. A p-value can be calcu-
lated for each set of genes by permuting the data multiple times and using (3) or
(4) or alternative methods. Various implementations of GSEA have been proposed
in the literature55–64. There are also several software implementations of GSEA. For
example, the Broad Institute offers software to perform GSEA in both Java and R
(http://www.broadinstitute.org/gsea/index.jsp) and a variant of GSEA is implemented
in the “SAM” software package.
The main shortcoming of GSEA is the fact that it tests a “competitive null hypothesis.”
Suppose we have two groups of genes, which we will call gene group 1 and gene group
2. Then a smaller p-value for testing the null hypothesis of no differential expression
in gene group 1 implies a larger p-value for testing this null hypothesis in gene group
2 even if the expression levels in gene group 2 remain unchanged. This occurs because
the p-value for gene group 2 is calculated by comparing the test statistics of the genes
in gene group 2 to the test statistics of all genes not in gene group 2, including the test
statistics in gene group 1. Thus, if extreme test statistics are observed in gene group 1,
this decreases the significance of gene group 2. See Damian and Gorfine 65 or Allison
et al. 29 for a more detailed discussion of this phenomena. The development of methods
for identifying groups of genes associated with an outcome of interest that avoids the
shortcomings of ORA and GSEA is an active research area.
Statistically Based Methods
Other strategies for combining information across genes use novel statistical methods
that do not require any knowledge of the biological relationship between the genes. We
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have previously discussed one possible statistical strategy for combining information
across genes, namely regularized or Bayesian estimators of the variance of individual
genes. By using information about the variance of other genes to estimate the variance
of a specific gene, the variance of the test statistic is greatly decreased, and hence the
risk of false positives and false negatives is also decreased. However, in recent years
there several more advanced methods have been proposed for combining information
across genes which we will briefly describe below.
One strategy is known as the optimal discovery procedure (ODP)66,67. The motivation
for ODP is similar to the motivation for the pathway-based methods discussed previ-
ously. Since genes function in pathways, we expect that genes in the same pathway are
likely to be co-expressed. Thus, if a gene shows evidence of differential expression,
one can be more confident that the differential expression is not due to chance if other
genes show a similar expression pattern. See Figure 6 for an illustration of this idea.
The difference between ODP and pathway-based methods is that pathway-based meth-
ods require one to know in advance which genes are expected to be co-expressed based
on previously collected biological data whereas ODP does not.
[Figure 6 about here.]
The ODP is a generalization of the Neyman-Pearson lemma68. The Neyman-Pearson
lemma states that the most powerful test of a given null hypothesis against a given
alternative hypothesis rejects the null hypothesis when the ratio
probability of the observed data under the alternative hypothesis
probability of the observed data under the null hypothesis (5)
is large. The ODP generalizes the Neyman-Pearson lemma to situations where multiple
hypotheses are tested by rejecting the null hypothesis that gene i is not differentially
expressed when the ratio
sum of the probabilities of observing data i under each alternative hypothesis
sum of the probabilities of observing data i under each null hypothesis (6)
is large. Thus, if a set of genes with similar expression patterns all show evidence of
differential expression, then (6) will be larger than (5) for a given gene in the set, mean-
ing that the null hypothesis of no differential expression is more likely to be rejected
under ODP than under the traditional Neyman-Pearson paradigm.
In practice, (6) cannot be computed exactly and must be approximated.66,67 Software
for computing the ODP is publicly available69.
An alternative strategy for combining information across genes without any biological
information about the relationship between the genes is the Lassoed Principal Compo-
nents (LPC) method of Witten and Tibshirani 70 . The motivation for LPC is similar to
the motivation for ODP: A gene is more likely to be differentially expressed if there
are other genes with similar expression patterns than it is if there are no such similar
genes. However, LPC uses a different strategy to determine if there are other genes
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with similar expression patterns. The idea behind LPC is that if a group of genes are
co-regulated, then it is likely that a principal component of the gene expression matrix
(sometimes called an eigenarray71) will capture the variance in this group of genes.
Thus, the LPC algorithm attempts to identify an eigenarray or group of eigenarrays
that are associated with the biological process of interest and projects the t-statistics
(or other relevant test statistics) onto this group of eigenarrays. This method can be
shown to significantly reduce the false discovery rate in a variety of situations.70 This
method is implemented in the “lpc” R package.
Clustering and Prediction Methods
Identifying features associated with an outcome of interest is not the only objective of
microarray studies. One may also wish to partition the data into homogeneous sub-
groups and/or use the data to predict an outcome of interest. Clustering methods and
prediction methods are useful in this situation.
There is a vast literature devoted to methods for clustering or predicting an outcome
based on microarray data. A full description of such methods is beyond this scope of
this review (which focuses on feature selection). However, it is noteworthy that there
are methods for clustering19,72–84 and prediction19,85–94 that also perform feature selec-
tion. These methods generally do not evaluate whether a selected gene is “statistically
significant” nor do they indicate which genes are the “most significant.” Also, the user
of these methods often has limited control over the number of features selected. Thus,
these methods have serious disadvantages if feature selection is the primary goal of
the analysis. Nevertheless these methods can identify a list of genes for further study,
particularly in cases where clustering and prediction are important goals of the experi-
ment.
Comparison of Feature Selection Methods
Numerous methods have been proposed for identifying significant features in DNA
microarray data. However, the question of which methods produce the best results
(i.e. maximize power while controlling type I error) has not been studied extensively.
In practice researchers often choose feature selection methods based on the ease of
implementing the method rather than the performance of the method. The “SAM”
software package has become a popular tool for microarray analysis largely due to
the fact that it is available as an Excel add-in and does not require the use of R or
command-line programs.
Limited research indicates that the “limma” method of Smyth 44 performs well for
a wide variety of problems, although other methods may perform better in specific
situations46,70,95. Limma is implemented in the “limma” R package, which is available
from Bioconductor. Determining which feature selection method is likely to produce
the best results on a given data set is an important area for future research.
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Issues Related to Multiple Hypothesis Testing
Identifying significant genes in microarray studies requires performing a large number
of hypothesis tests, which presents statistical challenges. When performing a single hy-
pothesis test, it is conventional to choose a significance level α such that the probability
of rejecting the null hypothesis when it is true is equal to α. However, when multiple
hypothesis tests are performed, the probability of at least one false positive test will be
much larger than α. Thus, methods are needed to control the number of false positive
tests while maintaining sufficient power to identify truly significant genes.
The Family-Wise Error Rate
One possible solution is to control the family-wise error rate (FWER) at a specified
level. The FWER is defined to be the probability of rejecting at least one null hypoth-
esis that is true. The most common way to control the FWER at a specified level is
to use a Bonferroni correction: Each individual null hypothesis is rejected if and only
p < α/N , where p is the p-value for the test and N is the total number of tests. It is
easy to show that the probability of at least one type I error is no greater than α using
this procedure.
Although the Bonferroni correction controls the number of false positive tests, it is
a very stringent criterion that typically results in a substantial loss of power. In ex-
periments with small sample sizes it is common for no tests to satisfy the Bonferroni
criteria. Thus, most microarray analysts prefer less stringent approaches29. Methods
exist for controlling the FWER using more permissive criteria than the Bonferroni cor-
rection3,96, but these methods also suffer from lower power and are not commonly
used.
The False Discovery Rate
The false discovery rate (FDR) is defined to be the expected proportion of false posi-
tives among the set of genes that are called significant. One may also adjust for multiple
comparisons by controlling the FDR rather than the FWER. This approach typically
yields greater power than FWER-based methods and hence is generally regarded as
preferable29.
The FDR was first proposed by Benjamini and Hochberg 97. To control the FDR at
a given level α, they proposed the following procedure: Let p(1) ≤ p(2) ≤ · · · ≤
p(N) be the ordered p-values, and let H(1), H(2), . . . , H(N) be the corresponding null
hypotheses. Then reject H(1), H(2), . . .H(j), where
j = max
i
{i : p(i) ≤ αi/N} (7)
Benjamini and Hochberg 97 prove that the FDR of this procedure is at most α. This
procedure is always valid if the p-values are independent. It remains valid in some cases
14
even when dependency exists among the p-values, and methods exist for estimating the
FDR where any type of dependency exists.98–110
Rather than choosing a specific FDR in advance, one may wish to estimate the FDR
when the top m genes are called significant. This is easy to do using the methodology
of Benjamini and Hochberg 97: If we let
αˆ = p(m)N/m (8)
Then (7) implies that the FDR should be approximately αˆ.
If one estimates the null distribution of the test statistics using permutations of the data
as in (3) and (4), then an alternative estimator of the false discovery rate may be used.
Once again, let tj denote the t-statistic (or other test statistic) associated with gene j,
and let tj,k denote the test statistic associated with gene j for the kth permuted data set.
Also, let t(1) ≤ t(2) ≤ · · · ≤ t(N) be the order statistics of the absolute values of the
tj’s. Then one may estimate the FDR αˆ when the top m genes are called significant as
follows:
αˆ =
1
mK
N∑
i=1
K∑
k=1
I(|ti,k| > t(N−m)) (9)
In other words, one estimates the FDR by dividing the average number of genes called
significant over K permuted data sets by the number of genes called significant in the
unpermuted data set (which is m, since the top m genes were called significant). It can
be shown that αˆ in (9) is a consistent estimator of the FDR99,111. Also, it can be shown
that estimators (8) and (9) are equivalent31. There are several R packages which will
compute the FDR using this methodology (such as the “multtest” package, which is
available from CRAN, and the “fdrame” package, which is available from Bioconduc-
tor). This methodology is also implemented in the “SAM” software package.
The Q-Value
In multiple testing problems, the q-value112 of a given test statistic t is defined to be the
smallest possible FDR that can occur among all possible rejection regions that reject
the null hypothesis when T = t. For example, if a t-statistic is calculated for each gene
and the jth such t-statistic is tj and |tj | = C, then the q-value for the jth hypothesis
test is the FDR for the rejection region |ti| ≥ C. In other words, the q-value is the
FDR that results when one calls gene j significant along with all other genes that have
a more extreme test statistic than gene j. Obviously genes with more extreme test
statistics will have smaller q-values. The q-value may be estimated using (8) or (9),
although other approaches are possible (see below). The q-value may be calculated
using the “qvalue” R package (available from Bioconductor) as well as the “SAM”
software package.
A Bayesian interpretation of the q-value is possible, as described in Storey 111 , Efron
and Tibshirani 113 and Storey 112 . Suppose that each gene comes from one of two pop-
ulations, one of which consists of genes that are differentially expressed, and the other
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which consists of genes that are not differentially expressed. Under this assumption,
the test statistic for each gene may be modeled using a mixture model. Define a set
of random variables Zj such that Zj = 0 if gene j is not differentially expressed and
Zj = 1 if gene j is differentially expressed. Also let |tj | = C, and let q(tj) be the
q-value corresponding to gene j. Then one can show111,114 that
q(tj) = P (Zj = 0||tj | ≥ C) (10)
In other words, under this mixture model, the q-value is the posterior probability that
the jth null hypothesis is true given the test statistic for gene j. Although we have
assumed a rejection region of the form |ti| ≥ C in (10), this result holds under more
general rejection regions.
Note: (10) is only true if we calculate the p-value based on the positive false discovery
rate (pFDR) as defined by Storey 111 rather than the traditional FDR proposed by Ben-
jamini and Hochberg 97. The pFDR is defined to be the expected proportion of false
positives among the set of genes that are called significant conditional on the fact that
at least one gene is called significant.
Methods exist for directly estimating the mixture distribution under the model de-
scribed above and thereby estimating the pFDR/q-value corresponding to individual
genes using (10) or similar procedures115–118. Limited research suggests that many
of these methods produce comparable results29,119. Such mixture models may also be
used for omnibus testing.120,121
Conclusion
Microarrays have been important for a variety of biological applications for over
a decade. However, technology for generating high-throughput biological data
is improving at a rapid pace, and technology that is commonly used today may
be replaced in the near future. Indeed, some have suggested that newer tech-
nologies such as RNA-seq may soon replace microarrays122 just as microar-
rays have largely replaced older techniques such as Northern blotting123. As
technology advances, new methods will be necessary for analyzing data sets
generated by the new techniques, and some methods for analyzing microarray
data may no longer be useful in the future if microarrays are replaced by newer
methods. Indeed, methods for identifying differentially expressed genes based
on RNA-seq data is currently an active research area.124–129
Despite these changing technologies, we feel that a discussion of methods
for analyzing microarray data is still relevant and timely. DNA microarrays are
still cheaper than RNA-seq assays, and RNA-seq gene expression measure-
ments can be unreliable for genes expressed at lower levels130. More impor-
tantly, however, many of the statistical techniques that have been developed
for analyzing microarray data can also be applied to data produced by other
high-throughput biological assays. For example, using normalized or Bayesian
estimators of the variance of an estimator is useful for performing feature se-
lection in any situation where the number of features is large and the number
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of observations is small. Similarly, use of the FDR and pFDR to control type I
error is useful for a wide variety of multiple testing problems, which arise in the
analysis of nearly all types of modern high-throughput biological data. For ex-
ample, the “SAM” software package for DNA microarray analysis was recently
upgraded to analyze RNA-seq data in addition to DNA microarray data. The
new method continues to use resampling-based approaches to estimate the
null distribution of each test statistic which is then used to estimate the FDR.
See Li and Tibshirani 129 for details. Likewise, GSEA and other pathway-based
methods for feature selection have been applied to genome-wide association
studies131–133. Thus, we see that the methods developed for DNA microarray
analysis will be useful for many years in the future even as technology changes.
Further Reading
Cui and Churchill 134 and Allison et al. 29 provide good overviews of feature
selection methods for microarray data. Jeffery et al. 46 describe several of the
most commonly used feature selection methods for microarrays and compare
the performance of these methods on 9 publicly available data sets. There are
also numerous books containing information on feature selection and other
aspects of microarray data analysis not considered in this review. Good refer-
ences include Causton et al. 135 , Parmigiani et al. 136 , Speed 137 , Wit and Mc-
Clure 138 , McLachlan et al. 139 , Do et al. 140 , and Draghici 141 .
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Figure 1: Illustration of a typical microarray experiment (using cDNA technology).
First, mRNA is extracted from two groups of cells, namely an experimental sample of
interest and a control sample. Each sample is labeled with a different color of fluores-
cent dye. The samples are then combined and hybridized onto an array. The relative
abundance of the mRNA corresponding to a particular gene can be measured by calcu-
lating the ratio of red dye to green dye at the appropriate spot on the array.
30
Figure 2: Image of a DNA microarray slide. One may measure the relative gene ex-
pression of each gene by comparing the ratio of the amount of red dye to the amount
of green dye at each probe on the array.
31
Figure 3: Heat map of the leukemia microarray data of Bullinger et al. 142 . Each col-
ored square on the map corresponds to the expression level of a given gene for a given
patient. In the above figure, each row represents a gene and each column represents a
patient. The brighter the color of a given square, the higher (or lower) the expression
level of the corresponding gene. Usually hierarchical clustering is performed on the
rows and columns of the data set prior to drawing the heat map.
32
2 4 6 8 10
0.
5
1.
0
1.
5
2.
0
2.
5 True Function
High Bias, Low Variance
Low Bias, High Variance
Figure 4: Illustration of the bias-variance trade-off. The above figure shows a regres-
sion problem where the objective is to predict y given a value of x. The dotted line
shows the true relationship between x and y. The linear regression estimator (shown in
blue) has high bias and low variance, and the interpolation estimator (shown in orange)
has low bias and high variance.
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Figure 5: Illustrates the association between the complexity of a model and the
bias/variance of the model. In general, as the complexity of a model increases, the
variance of the model increases and the bias of the model decreases.
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Figure 6: Illustration of the ODP procedure. Suppose that the test statistic for the null
hypothesis of no differential expression is t = −2 for one gene and t = 2 for a second
gene. Suppose further that there are several other genes with similar expression patterns
to the second gene for which t ≈ 2. Using traditional hypothesis testing procedures,
one would be equally likely to reject the null hypothesis of no differential expression
for both of the two genes. Using ODP, one would be more likely to reject the null
hypothesis for the gene where t = 2, since the existence of several genes with similar
expression patterns increases ones confidence that the result is not due to chance.
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